藥明巨諾(02126.HK)細胞免疫治療藥物完成200位中國患者回輸治療
藥明巨諾(02126.HK)宣布,截至2022年4月12日,其細胞免疫治療藥物已成功完成200位中國患者的回輸治療,包含臨床研究及商業化階段。
公司表示,已成功打造細胞免疫治療技術與產品開發平台,以及涵蓋血液及實體腫瘤的產品管線,目前已開展9項針對血液、實體腫瘤的臨床研究,未來將繼續引入及開發更多前沿技術,持續推進血液及實體腫瘤的產品管線,大規模降低生產成本,為患者帶來治癒希望。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.